CBCE - Activity Details

Fifth Annual Fall Oncology Conference

Renaissance Ross Bridge Golf Resort & Spa
October 25, 2008

Program Description
Please join us for a day-long intensive review of the most important advances to impact clinical practice in oncology from this year. Clinical experts from across the country will deliver didactic and interactive presentations on key data to emerge from this year’s major scientific meetings, and will discuss how these findings can be translated into patient care.

Sessions will evaluate the impact of advances in the treatment of cancer, including novel therapies, combined-modality therapy, and individualized, flexible approaches to patient management.

Highlights include:

New approaches for both early-stage and metastatic breast cancer
Clinical trial results evaluating chemotherapeutic and radiotherapeutic approaches to the management of NSCLC
Recent developments in GI cancer
New clinical trial data for the treatment of mCRC
Novel agents for the treatment of RCC

Benefits:

Opportunity to interact with clinical experts on the issues most relevant
to your practice
Condensed 1-day format covers the most relevant clinical trial data from 2008

Statement of Need

For many solid tumors, the treatment of choice in the early stage is typically surgical resection followed by radiotherapy (RT), with or without chemotherapy, depending on the performance status of the patient. In the late stages, palliative chemotherapy or RT is usually the treatment of last resort. However, patient prognosis even after these interventions often remains poor, and therapy can be accompanied by severe toxicity. More effective and less toxic therapies are needed. Advances in radiation delivery technology are bringing improvements in efficacy with less treatment-related morbidity and toxicity. In addition, as the molecular details of tumor growth, angiogenesis, and progression become known, novel agents that target these pathways are being developed. These molecularly targeted agents, as well as novel cytotoxic drugs, are being actively investigated as potential systemic therapies, including combinations with chemotherapy and RT, for multiple tumor types. Finally, new approaches to choosing and sequencing therapeutic regimens and modalities, especially in advanced disease, hold the potential for prolonging survival and decreasing treatment toxicity. At the end of this program, participants will be able to evaluate the impact of advances in the treatment of cancer, including novel therapies, combined-modality therapy, and individualized, flexible approaches to patient management.

Target Audience
This activity is designed for community oncologists, radiation oncologists, surgical oncologists, oncology nurses, research nurses/coordinators, pharmacists, physician assistants, and other healthcare professionals interested in the treatment of patients with cancer.

Educational Objectives
Upon completion of this activity, participants will be able to
1. Assess the safety and efficacy of new approaches for the treatment of breast cancer in both the early-stage and metastatic settings based on recent clinical studies.
2. Compare the efficacy of available treatment regimens with those currently being developed for the treatment of GI cancer based on the results of recent clinical trials.
3. Assess recent clinical trial data investigating targeted agents in the treatment of patients with mCRC as well as key principles guiding patient selection and sequencing of therapy for mCRC.
4. Describe recent clinical trials investigating the safety and efficacy of novel agents for the treatment of RCC.
5. Describe recent clinical trial results evaluating chemotherapeutic and radiotherapeutic approaches to managing patients with NSCLC.

Method of Participation
Lectures, visual aids, presentations, and discussion will be utilized to engage attendees and enhance the learning process.

Accreditation Statement

Physicians: This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the CBCE™ (The Center for Biomedical Continuing Education) and Vanderbilt-Ingram Cancer Center Affiliate Network. The CBCE is accredited by the ACCME to provide continuing medical education for physicians.

The CBCE designates this educational activity for a maximum of 4.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in this activity.

Physician Assistants: AAPA accepts certificates of participation for educational activities certified for Category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 4.5 hours of Category 1 credit for completing this program.

Nurses: The CBCE™ (The Center for Biomedical Continuing Education) is accredited as a provider of continuing nursing education by the American Nurses Credentialing
Center’s Commission on Accreditation.

The CBCE designates this educational activity for 4.5 contact hours. Accreditation by the American Nurses Credentialing Center’s Commission on Accreditation refers to recognition of educational activities and does not imply approval or endorsement of any product.

Pharmacists: The CBCE™ (The Center for Biomedical Continuing Education) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.
CPE Credit: 4.5 contact hours or0.450 CEUs
Universal Program Number: 195-999-08-012-L01-P

Certificate
The Evaluation and Request for Credit Form must be completed and returned to the CBCE following this activity to obtain credit. Participants will receive their certificate 4-6 weeks after the CBCE receives their form.

Acknowledgement of Commercial Support
The CBCE and Vanderbilt-Ingram Cancer Center Affiliate Network gratefully acknowledge the educational grants provided by multiple commercial supporters. To date, we have received educational grants from Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals, Inc.; Genentech BioOncology/OSI Pharmaceuticals, Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; and Wyeth Pharmaceuticals.

Americans With Disabilities Act (ADA)
The CBCE and Vanderbilt-Ingram Cancer Center Affiliate Network fully comply with the legal requirements of the ADA and the rules and regulations thereof. If any participant in this educational activity is in need of support services, please notify the CBCE staff at the conference registration desk in order to receive service.

Educational Inquiries
For further information, please contact the CBCE, 1707 Market Place Blvd., Suite 370, Irving, Texas 75063; Telephone: (214) 260-9024; Fax: (214) 260-0509; E-mail: info@thecbce.com.

Disclaimer
The content and views presented in this educational activity are those of the faculty and do not necessarily reflect the opinions or recommendations of the CBCE; Vanderbilt- Ingram Cancer Center Affiliate Network; Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals, Inc.; Genentech BioOncology/OSI Pharmaceuticals, Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; or Wyeth Pharmaceuticals. This material has been prepared based on a review of multiple sources of information, but is not exhaustive of the subject matter. Participants are advised to critically appraise the information presented, and are encouraged to consult the available literature on any product or device mentioned in this program.

Disclosure of Unlabeled Uses
This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the US Food and Drug Administration. For additional information about approved uses, including approved indications, contraindications, and warnings, please refer to the prescribing information for each product, or consult the Physicians’ Desk Reference.

Disclosure of Financial Relationships With Any Commercial Interest

As a provider accredited by the ACCME, it is the policy of the CBCE to require that everyone who is in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest, and identify and resolve all conflicts of interest prior to the educational activity. The CBCE defines “relevant financial relationships” as any amount occurring within the past 12 months.

Financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (eg, stocks, stock options, or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities for which remuneration is received or expected. The CBCE considers relationships of the person involved in the educational activity to include financial relationships of a spouse or partner.

Faculty who refuse to disclose relevant financial relationships will be disqualified from being a planning committee member, a teacher, or an author, and cannot have control of, or responsibility for, the development, management, presentation, or evaluation of the educational activity. For an individual with no relevant financial relationship(s), the learners must be informed that no relevant financial relationship(s) exists.

Disclosure of Potential Conflicts of Interest

The CBCE assesses conflicts of interest with its faculty, planners, and managers of CBCE activities. Identified conflicts of interest are thoroughly evaluated by the Planning Committee for fair balance, scientific objectivity relative to studies utilized in this activity, and patient-care recommendations. The CBCE is committed to providing its learners with high-quality, unbiased, and state-of-the-art education.

The following faculty reported real or apparent conflicts of interest, and these conflicts have been resolved through a peer-review process:

Walter J. Curran Jr, MD, FACR
Consultant
Amgen Inc.
AstraZeneca Pharmaceuticals LP
Bristol-Myers Squibb Company
Eli Lilly and Company
Genentech, Inc.
ImClone Systems Incorporated
OSI Pharmaceuticals, Inc.

Carla Falkson, MD
Consultant
Amgen Inc.
Honoraria
Genentech, Inc.
Ownership Interest
Johnson & Johnson
sanofi-aventis

Laura Williams Goff, MD
Honoraria
Bayer HealthCare Corporation/Onyx Pharmaceuticals, Inc.

Bert H. O’Neil, MD
Consultant
AstraZenenca Pharmaceuticals LP
Honoraria
Amgen Inc.
Bristol-Myers Squibb Company
Pfizer Inc.
sanofi-aventis

Alan B. Sandler, MD
Consultant
Amgen Inc.
Bristol-Myers Squibb Company
Eli Lilly and Company
Genentech, Inc.
Novartis Pharmaceuticals Corporation
Pfizer Inc.
Grant/Research Support
AstraZenenca Pharmaceuticals LP
Bayer Pharmaceuticals Corporation
Bristol-Myers Squibb Company
Cyclacel Pharmaceuticals, Inc.
Eli Lilly and Company
Genentech, Inc.
OSI Pharmaceuticals, Inc.
Wyeth Pharmaceuticals
Honoraria
Bristol-Myers Squibb Company
Eli Lilly and Company
Genentech, Inc.

Jeffrey A. Sosman, MD
Consultant
Bayer HealthCare Corporation/Onyx Pharmaceuticals, Inc.
Genentech, Inc.
Grant/Research Support
Genentech, Inc.
Pfizer Inc.
Wyeth Pharmaceuticals

Heather Wakelee, MD
Grant/Research Support
Cell Therapeutics, Inc.
Eli Lilly and Company
Exelixis, Inc.
Genentech, Inc.

The following faculty declared they have no financial relationships that require disclosure:

Brian Leyland-Jones, MD, PhD

The following VICCAN staff declared they have no relevant financial relationships that require disclosure:

Nancy Muldowney
Laura Stackhouse

Institutional Disclosure
The CBCE receives educational grants from the pharmaceutical industry and other commercial sources. Companies providing grants to the CBCE include the commercial supporters of this activity as well as the manufacturers of certain drugs and/or devices discussed in this activity.

Staff Disclosure
The CBCE staff have declared they have no financial relationships that require disclosure.

Chair(s)

Alan B. Sandler, MD
Associate Professor of Medicine
Director, Thoracic Oncology Program
Vanderbilt-Ingram Cancer Center
Medical Director, Vanderbilt-Ingram Cancer Center Affiliate Network

Faculty

Walter J. Curran, Jr, MD, FACR
Lawrence Davis Professor and Chair
Emory University

Carla Falkson, MD
Professor
University of Alabama at Birmingham

Brian Leyland-Jones, MD, PhD
Associate Vice President and Director, Winship Cancer Institute
Emory University

Bert H. O`Neil, MD
Associate Professor, Clinical Research
Lineberger Comprehensive Cancer Center
The University of North Carolina at Chapel Hill

Caio Max S. Rocha Lima, MD
Associate Professor of Medicine
University Of Miami Sylvester Comprehensive Cancer Center

Jeffrey A. Sosman, MD
Professor of Medicine
Vanderbilt University Medical Center
Division of Hematology Oncology
Leader, Melanoma Program
Co-Leader, Cell Proliferation and Signal Transduction Program
Vanderbilt-Ingram Cancer Center

Heather Wakelee, MD
Assistant Professor of Medicine, Oncology
Stanford University School of Medicine
Stanford Comprehensive Cancer Center

Laura Williams Goff, MD
Assistant Professor of Medicine
Vanderbilt Medical Center

Saturday, October 25 2008

Session I: Breast Cancer
Session II: Gastrointestinal Cancer
Session III: Lung Cancer
Special Topic
7:00 - 8:00 AM	Registration and Breakfast
8:00 - 8:05 AM	Welcome and Introductions	Alan B. Sandler
8:05 - 8:35 AM	Current Approaches to the Adjuvant Therapy of Breast Cancer	Brian Leyland-Jones
8:35 - 8:55 AM	New Directions in the Management of Advanced Breast Cancer	Carla Falkson
8:55 - 9:05 AM	Panel Discussion
9:05 - 9:20 AM	Break
9:20 - 9:45 AM	Keynote Lecture: Pancreatic Cancer: An Opportunity for Drug Development	Caio Rocha-Lima
9:45 - 10:05 AM	Optimizing Patient Outcomes Through Individualized Treatment Strategies for CRC	Bert O'Neil
10:05 - 10:25 AM	New Options for the Treatment of Hepatocellular Carcinoma	Laura Williams Goff
10:25 - 10:40 AM	Panel Discussion
10:40 - 11:05 AM	Renal Cancer: Newly Approved Agents and Their Effect on the Standard of Care	Jeffrey A. Sosman
11:05 - 11:10 AM	Panel Discussion
11:10 - 11:30 AM	Resectable Adjuvant Lung Cancer	Heather Wakelee
11:30 - 11:50 AM	Role of RT in the Management of SCLC and NSCLC	Walter Curran
11:50 AM - 12:10 PM	Metastatic Lung Cancer	Alan B. Sandler
12:10 - 12:40 PM	Round Table: Future Directions of Lung Cancer	Heather Wakelee, Walter Curran, Alan Sandler
12:40 - 12:55 PM	Evaluations
6:30 - 7:00 PM	Group Reception
7:00 - 9:00 PM	Group Dinner

Renaissance Ross Bridge Golf Resort & Spa

Renaissance Ross Bridge Golf Resort & Spa
Hoover, AL
Conveniently located outside of Birmingham, AL

http://www.rossbridgeresort.com/

Conference Room Rate
Room accommodations for this conference are $189 per night, single or double occupancy, with an approximate 14% applicable state and local sales and occupancy tax. The maximum number of people per guest room is 4.

Reservation Guarantee
An early response is suggested for guests desiring the group rate. To ensure the group rate, reservations must be made through the CBCE by Friday, September 25, 2008. After September 25, 2008, no guarantee is provided for accommodation availability or our room rate at the Renaissance Ross Bridge.* Room type and group room rate are subject to availability. Check-in time is 4:00 PM. All reservations must be guaranteed with a 1-night room deposit or a major credit card. A credit card is necessary to guarantee a late arrival. All major credit cards are accepted by Renaissance Ross Bridge.

*If needed, the CBCE will make appropriate overnight accommodations for you at a nearby property (subject to availability).

Hotel Cancellation Policy
No-shows will be charged the full amount of the reservation. Any guaranteed rooms cancelled less than 7 days prior to the day of arrival will be charged the full amount. If the hotel is able to resell the reservation, you will not be charged the cancellation fee.

Climate
The climate in Hoover, AL, in October is cool with temperatures ranging from an average daily low of 51ºF to an average daily high of 75ºF. A jacket is recommended.

Limousine and Rental Car Services
Reservations can be made through the Renaissance Ross Bridge ground transportation office by calling (205) 949-3114, or you may call (866) 480-7677 and ask for the concierge.

Parking
Valet parking is available for $16; self-parking is complimentary.

Taxi
If you wish to take a taxi to the hotel, expect an approximate $55 fare from Birmingham International Airport.

Conference Cancellation Policy
If a cancellation notice is received by the CBCE in writing by October 10, 2008, 75% of the registration fee will be refunded. All cancellation requests should be sent to the CBCE at the address below.

The CBCE
1707 Market Place Blvd., Suite 370
Irving, TX 75063

Registration Fees
The registration fee covers participation at all conference sessions, meeting materials, and food functions per the agenda.

Physician, nurse, and pharmacist early-bird registration (registration must be received and paid in full by Thursday, September 25, 2008): $50
(in practice or academic research; fax, postdate, or register online with registration fee by date above to be eligible for discount)
Physician (in practice or academic research): $75
Nurse, pharmacist, and other healthcare professionals (in practice or academic research): $60
Fellow (in practice or academic research): Complimentary, with letter of status from director
Industry/all others: $895.00 (This category is defined by the CBCE as any person employed by a for-profit organization, including biotech, financial, and pharmaceutical.)
VICCAN Affiliate: Complimentary